Quick Answer
Xeris Biopharma Holdings, Inc. reported Revenue (ASC 606) of $291.85 million for fiscal year 2025.
Xeris Biopharma Holdings, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $291.85M | +43.7% |
| 2024 | $203.07M | +23.9% |
| 2023 | $163.91M | +48.7% |
| 2022 | $110.25M | +122.3% |
| 2021 | $49.59M | +146.0% |
| 2020 | $20.16M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $74.38M | +37.1% | +4.0% |
| June 30, 2025 | $71.54M | +48.8% | +19.0% |
| March 31, 2025 | $60.12M | +47.9% | +10.8% |
| September 30, 2024 | $54.27M | +12.3% | +12.9% |
| June 30, 2024 | $48.06M | +26.5% | +18.3% |
| March 31, 2024 | $40.64M | +22.4% | -15.9% |
| September 30, 2023 | $48.32M | +62.6% | +27.1% |
| June 30, 2023 | $38.01M | +50.2% | +14.5% |
- Xeris Biopharma Holdings, Inc. showed an increase of +43.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2025 period, Xeris Biopharma Holdings, Inc.’s revenue (asc 606) has grown by 1348.0% (from $20.16 million to $291.85 million).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: